In DM patients, P2Y12 inhibitor monotherapy significantly lowered the risk of MACCE compared to standard 12-month DAPT (OR: 0.85, 95% CI: 0.74–0.98, p = 0.02, I2 = 0%, PHeterogeneity = 0.62). This evidence concerns the gene P2RY12 and diabetes mellitus.